ライフサイエンスコーパス: artemether

1 uine (MFQ)-artesunate and lumefantrine (LUM)-artemether.

2 more potent than the clinically used acetal artemether.

3 6)) and other C-10 ether derivatives such as artemether.

4 o the ART derivatives dihydroartemisinin and artemether.

5 200 uL of whole blood along with 20 mg/kg of artemether.

6 e-stage CM from 27.5% to 51.6% compared with artemether.

7 m berghei ANKA, comparable to artesunate and artemether.

8 ues of the potent first-generation analogues artemether (4a) and arteether (4b) have been designed an

9 al potency with an ED(50) of 2.12 mg/kg (cf. artemether = 6 mg/kg) versus P. berghei.

10 temisinin derivatives such as artesunate and artemether, along with the fully synthetic endoperoxide

11 antrine (four tablets, each containing 20 mg artemether and 120 mg lumefantrine, given twice per day

12 Participants received either 80 mg of oral artemether and 480 mg of oral lumefantrine twice daily f

13 xicity than the first-generation derivatives artemether and arteether.

14 As artemether and artesunate are derivatives of artemisinin

15 greatly from the semi-synthetic artemisinins artemether and artesunate as they rapidly reduce parasit

16 superior to the currently used derivatives, artemether and artesunate.

17 Participants received combined artemether and lumefantrine (four tablets, each containi

18 phosphate (AM-PQP) in comparison to Coartem (artemether and lumefantrine) in patients with acute unco

19 f 33, 84.8% for AQ-13 vs 31 of 33, 93.9% for artemether and lumefantrine; p=0.43) but the upper bound

20 Coadministration of artemether and nimodipine, a calcium channel blocker use

21 creased sensitivities to dihydroartemisinin, artemether and piperaquine - an ACT partner drug in this

22 eatments (artesunate, dihydroartemisinin, or artemether) and miscarriage or malformation was assessed

23 ds such as the medical drugs pravastatin and artemether, and the steroid hormone testosterone.

24 Artemether (ART) and lumefantrine (LUM) are the gold sta

25 ic drugs for severe and complicated malaria (artemether, artesunate) was prompt.

26 mine the in vitro parasite susceptibility to artemether (ATH).

27 r cerebral malaria we conclude that although artemether clears parasitemia more rapidly than quinine,

28 Pharmacokinetic sampling for artemether, dihydroartemisinin, and lumefantrine exposur

29 ose) or 5-day (10-dose) AL with sampling for artemether, dihydroartemisinin, and lumefantrine over 42

30 exposure by 2.1-fold; and nevirapine reduced artemether exposure only.

31 with dihydroartemisinin derivatives such as artemether have spawned a renewed effort to develop nont

32 0.25-0.42 microM), comparable in potency to artemether (IC(50) = 0.31 microM) and >100 times more in

33 han artemisinin and about twice as active as artemether in vitro versus chloroquine-resistant parasit

34 e clinical antimalarial drugs artesunate and artemether, in which a major metabolically sensitive sit

35 ate + amodiaquine (AS + AQ), 7.42% following artemether + lumefantrine, and 6.80% following DHA + PIP

36 ine plus amodiaquine (22 [1.3%] of 1703) and artemether-lumefantrine (11 [0.6%] of 1721) was infreque

37 a recurrence of malaria after treatment with artemether-lumefantrine (28.1% vs. 54.2%; hazard ratio,

38 269 [24%]), artesunate-mefloquine (73 [7%]), artemether-lumefantrine (289 [26%]), or artemether-lumef

39 86; 95% CI 97 to 99]) was similar to that of artemether-lumefantrine (97% [279 of 289; 95% CI 94 to 9

40 d either AM-PQP (714 patients) once daily or artemether-lumefantrine (A-L; 358 patients) twice daily

41 ater than for the comparator group receiving artemether-lumefantrine (adjusted difference -1.46 g/dL;

42 2:1 to AM-PQP (571 patients) once daily and artemether-lumefantrine (AL) (288 patients) twice daily

43 In Uganda, artemether-lumefantrine (AL) and dihydroartemisinin-pipe

44 Two major antimalarial policy options are artemether-lumefantrine (AL) and dihydroartemisinin-pipe

45 sinin-based combination therapies, including artemether-lumefantrine (AL) and dihydroartemisinin-pipe

46 arriage was faster when PQ was combined with artemether-lumefantrine (AL) compared to dihydroartemisi

47 arriage was faster when PQ was combined with artemether-lumefantrine (AL) compared to dihydroartemisi

48 Since the introduction of artemether-lumefantrine (AL) for treatment of uncomplica

49 ndomized for treatment with AQ-SP, AS-AQ, or artemether-lumefantrine (AL) for uncomplicated malaria.

50 In treating malaria in Uganda, artemether-lumefantrine (AL) has been associated with a

51 for Plasmodium vivax in malarious areas, but artemether-lumefantrine (AL) is also commonly used.

52 Artemether-lumefantrine (AL) is the first-line antimalar

53 Artemether-lumefantrine (AL) is the most widely used art

54 Artemether-lumefantrine (AL) is the most widely-recommen

55 trial in Western Kenya randomized to receive artemether-lumefantrine (AL) or artesunate-mefloquine (A

56 ay outcomes following malaria treatment with artemether-lumefantrine (AL) or dihydroartemisinin-piper

57 parasite carriers were randomized to receive artemether-lumefantrine (AL) plus placebo or AL plus a s

58 s using the >= 2/3 and 3/3 algorithms in the artemether-lumefantrine (AL) treatment arm, while msp-1/

59 Artemether-lumefantrine (AL) was significantly more pote

60 s of dihydroartemisinin-piperaquine (DP) and artemether-lumefantrine (AL) with or without primaquine

61 signed to receive either chloroquine (CQ) or artemether-lumefantrine (AL), alone or in combination wi

62 the effects of the most widely-deployed ACT, artemether-lumefantrine (AL), relative to non-ACTs on ga

63 Each malaria episode was treated with artemether-lumefantrine (AL).

64 (DHA-PPQ), artesunate-amodiaquine (ASAQ), or artemether-lumefantrine (AL).

65 tive were treated with a six dose regimen of artemether-lumefantrine (AL).

66 2,711 (17.7%) patients were treated with artemether-lumefantrine (AL, 13 studies), 651 (4.2%) wit

67 icated falciparum malaria were randomized to artemether-lumefantrine (AL; n = 153) or dihydroartemisi

68 nate (n=515), or a 3-day six-dose regimen of artemether-lumefantrine (n=519).

69 % CI 91.0-94.3) versus 80.4% (77.8-83.0) for artemether-lumefantrine (n=671).

70 rtesunate, and 6.7% (95% CI, 3.9%-11.2%) for artemether-lumefantrine (P<.05 for all pairwise comparis

71 r treatment was 100% (IQR 100 to 100) in the artemether-lumefantrine (p=0.0018), artemether-lumefantr

72 to initiate infection, and were treated with artemether-lumefantrine (Study 1) or chloroquine (Study

73 ggest that the current first-line treatment (artemether-lumefantrine + primaquine) is still useful ag

74 us liver-stage drugs (chloroquine [CQ], 3 d; artemether-lumefantrine [AL], 3 d; and primaquine [PQ],

75 Subjects were treated with artemether-lumefantrine after development of clinical sy

76 These data support the effectiveness of artemether-lumefantrine alone for preventing nearly all

77 Our findings support the effectiveness of artemether-lumefantrine alone or as part of TACT for pre

78 00.0% (IQR 100.0-100.0; n=19; p=0.0011) with artemether-lumefantrine and 100.0% (100.0-100.0; n=19; p

79 on artemisinin combination therapies (ACTs, artemether-lumefantrine and artesunate-mefloquine) where

80 ale spp. infected patients were treated with artemether-lumefantrine and followed biweekly for up to

81 baseline infected mosquitoes on day 2 after artemether-lumefantrine and none at day 5.

82 rapid diagnostic testing and treatment with artemether-lumefantrine and single-dose primaquine, rfMD

83 , focal interventions (chemoprevention using artemether-lumefantrine and/or indoor residual spraying

84 ther markers for decreased susceptibility to artemether-lumefantrine are common: P falciparum multidr

85 g or up to 50 mg once daily for 3 days, with artemether-lumefantrine as control.

86 care for severe anemia and a 3-day course of artemether-lumefantrine at discharge.

87 First-line treatment was switched from SP to artemether-lumefantrine before the final survey, when SP

88 malaria screening and treatment (CSST) with artemether-lumefantrine by community health workers (CHW

89 ndomly allocated 468 participants to receive artemether-lumefantrine combined with placebo (119 child

90 rapidly eliminated ACT: 15.3% (5.1-29.3) for artemether-lumefantrine compared with 4.5% (1.2-9.3) for

91 e >=1.4 at baseline were linked to decreased artemether-lumefantrine day 42 efficacy (79% vs 97% sing

92 Further refinement of artemether-lumefantrine dosing to improve exposure in in

93 om recent dihydroarteminisin-piperaquine and artemether-lumefantrine efficacy trials in Rwanda(7).

94 Adding amodiaquine to artemether-lumefantrine extended the electrocardiogram c

95 ence to receive home delivery of prepackaged artemether-lumefantrine for presumptive treatment of feb

96 an for malaria treatment, including stocking artemether-lumefantrine for uncomplicated malaria, and s

97 of the malaria transmission season, monthly artemether-lumefantrine given at the end of weeks 4 and

98 rtemisinin-piperaquine group (20.6%) and the artemether-lumefantrine group (11.5%) (P<0.001 for compa

99 ctic effect, were significantly lower in the artemether-lumefantrine group (52.5%) than in groups tha

100 The cure rate in the artemether-lumefantrine group was significantly lower th

101 the per-protocol analysis were 94.8% in the artemether-lumefantrine group, 98.5% in the amodiaquine-

102 t day 2, two (10%) of 20 participants in the artemether-lumefantrine group, two (11%) of 19 in the ar

103 fectious individuals from baseline to day 2 (artemether-lumefantrine groups) or day 7 (sulfadoxine-py

104 ents in the United Kingdom (UK) treated with artemether-lumefantrine have implications for malaria ch

105 nts received blood schizontocidal treatment (artemether-lumefantrine in Ethiopia and Bangladesh and d

106 In facilities with artemether-lumefantrine in stock, this antimalarial was

107 In the first trimester, artemether-lumefantrine is approved, and safety data are

108 The WHO-packaged six-dose regimen of artemether-lumefantrine is effective taken unsupervised,

109 If artemether-lumefantrine is unavailable, other ACTs (exce

110 Artemether-lumefantrine is widely used for uncomplicated

111 We assessed the effect of home delivery of artemether-lumefantrine on the incidence of antimalarial

112 bination with mass treatment strategies with artemether-lumefantrine on transmission metrics.

113 ic of the Congo they were assigned to either artemether-lumefantrine or artemether-lumefantrine plus

114 ith malaria were randomized and treated with artemether-lumefantrine or cipargamin.

115 Overall, 312 children were randomized to artemether-lumefantrine or dihydroartemisinin-piperaquin

116 treatment are a group experiencing decreased artemether-lumefantrine performance.

117 Vomiting after artemether-lumefantrine plus amodiaquine (22 [1.3%] of 1

118 %]), artemether-lumefantrine (289 [26%]), or artemether-lumefantrine plus amodiaquine (286 [26%]).

119 The overall 42-day PCR-corrected efficacy of artemether-lumefantrine plus amodiaquine (98% [281 of 28

120 oartemisinin-piperaquine plus mefloquine and artemether-lumefantrine plus amodiaquine TACTs are effic

121 ssigned to either artemether-lumefantrine or artemether-lumefantrine plus amodiaquine.

122 The substantial over-treatment suggests that artemether-lumefantrine provided in the home might not b

123 nstant in untreated children, treatment with artemether-lumefantrine reduced the gametocyte prevalenc

124 Notwithstanding, efficacy of artemether-lumefantrine remained high in Rwanda, with a

125 Artemether-lumefantrine remains highly efficacious in 3

126 n frequencies similar to the mainland, where artemether-lumefantrine selects for mutations favoring a

127 lity and antimalarial effectiveness of ACTs, artemether-lumefantrine should be considered the preferr

128 of adverse pregnancy outcomes was lower with artemether-lumefantrine than with oral quinine in the fi

129 l was carried out based on directly observed artemether-lumefantrine therapy at Bengo, Northern Angol

130 Curative artemether-lumefantrine therapy was administered if para

131 At enrollment, all participants received artemether-lumefantrine to clear possible P. falciparum

132 At enrollment, all the participants received artemether-lumefantrine to clear possible P. falciparum

133 We confirm, in a documented case of artemether-lumefantrine treatment failure imported from

134 The high rates of artemether-lumefantrine treatment failures suggest surve

135 The parasite clearance half-life following artemether-lumefantrine treatment was 6.7 hours.

136 al follow-up for recurrent malaria following artemether-lumefantrine treatment, along with the study

137 the pharmacokinetics and pharmacodynamics of artemether-lumefantrine treatment.

138 Artemether-lumefantrine was administered following the f

139 Given that treatment with artemether-lumefantrine was associated with fewer advers

140 Artemether-lumefantrine was associated with the fewest a

141 Artemether-lumefantrine was better tolerated than QnC (p

142 Introduction of artemether-lumefantrine was followed by an increase in d

143 Artemether-lumefantrine was the most efficacious treatme

144 ) to receive either artemether-lumefantrine, artemether-lumefantrine with a single dose of 0.25 mg/kg

145 We aimed to determine the efficacy of artemether-lumefantrine with and without primaquine and

146 culated and, on day 8, randomized to receive artemether-lumefantrine with either ruxolitinib or place

147 nd 100.0% (100.0-100.0; n=19; p=0.0001) with artemether-lumefantrine with primaquine.

148 ridine-artesunate efficacy was compared with artemether-lumefantrine with the adequate clinical and p

149 mbination therapy (artesunate-amodiaquine or artemether-lumefantrine) for uncomplicated malaria in Er

150 rimethamine, amodiaquine plus artesunate, or artemether-lumefantrine) when diagnosed with their first

151 nd regardless of symptoms) were treated with artemether-lumefantrine, amodiaquine-artesunate, mefloqu

152 e, rfMDA involved presumptive treatment with artemether-lumefantrine, and RAVC involved indoor residu

153 andomly assigned (1:1:1:1) to receive either artemether-lumefantrine, artemether-lumefantrine with a

154 omly allocated (1:1:1:1:1) to receive either artemether-lumefantrine, artemether-lumefantrine-amodiaq

155 We compared simultaneous distribution of artemether-lumefantrine, artesunate-amodiaquine, and dih

156 ning mefloquine or piperaquine compared with artemether-lumefantrine, but by day 63 the risk of vivax

157 D alleles were selected after treatment with artemether-lumefantrine, but not after artesunate-amodia

158 a and normal G6PD enzyme function to receive artemether-lumefantrine, combined with either placebo or

159 nd genuine antimalarial samples (artesunate, artemether-lumefantrine, dihydroartemisinin-piperaquine

160 the most widely used treatment for malaria, artemether-lumefantrine, has not been adequately charact

161 isons, except amodiaquine plus artesunate vs artemether-lumefantrine, P = .05).

162 Comparator interventions included placebo, artemether-lumefantrine, sulfadoxine-pyrimethamine (SP),

163 results raise concern regarding activity of artemether-lumefantrine, the first-line antimalarial in

164 Decreased efficacy of artemether-lumefantrine, the globally most used antimala

165 Compared to artemether-lumefantrine, the use of DP to treat uncompli

166 mears on day 14, when they were treated with artemether-lumefantrine, with rapid clinical and parasit

167 ) in the artemether-lumefantrine (p=0.0018), artemether-lumefantrine-amodiaquine (p=0.0018), and arte

168 imed to determine the safety and efficacy of artemether-lumefantrine-amodiaquine and artesunate-amodi

169 r-lumefantrine group, two (11%) of 19 in the artemether-lumefantrine-amodiaquine group, and 15 (75%)

170 her-lumefantrine-amodiaquine (p=0.0018), and artemether-lumefantrine-amodiaquine plus primaquine (p=0

171 ntrine, artemether-lumefantrine-amodiaquine, artemether-lumefantrine-amodiaquine plus primaquine, art

172 either artesunate-mefloquine-piperaquine or artemether-lumefantrine-amodiaquine resulted in lower lo

173 ) to receive either artemether-lumefantrine, artemether-lumefantrine-amodiaquine, artemether-lumefant

174 s of uncomplicated malaria were treated with artemether-lumefantrine.

175 e recurrence of malaria after treatment with artemether-lumefantrine.

176 ing up to about 60 days after treatment with artemether-lumefantrine.

177 aquine+artesunate, and seven of 502 (1%) for artemether-lumefantrine.

178 twice failed treatment with full courses of artemether-lumefantrine.

179 th median PCT of 8 hours versus 24 hours for artemether-lumefantrine.

180 eater when paired with chloroquine than with artemether-lumefantrine.

181 d to the current approach of a 3-d course of artemether-lumefantrine.

182 nd since 2006 the first-line antimalarial is artemether-lumefantrine.

183 e mosquito feeding assays, then treated with artemether-lumefantrine.

184 nd treated students who tested positive with artemether-lumefantrine.

185 dren with malaria were promptly treated with artemether-lumefantrine.

186 risk of death compared to those treated with artemether-lumefantrine.

187 opted artemisinin-based combination therapy, artemether-lumefantrine.

188 op immunity more slowly than those receiving artemether-lumefantrine.

189 isodes of Plasmodium falciparum malaria with artemether-lumefantrine.

190 t assessed the efficacy and effectiveness of artemether-lumefantrine.

191 atment failure rate following treatment with artemether/lumefantrine (AL).

192 participants requiring rescue treatment with artemether/lumefantrine due to the onset of parasitemia

193 that contained/claimed to contain artesunate/artemether (n = 26), falsified antimalarials had a range

194 with ECM (75.9% compared to 50.9% receiving artemether only).

195 of 33; p=0.50) and AQ-13 was not inferior to artemether plus lumefantrine (difference -6.1%, 95% CI -

196 therapies of artesunate plus amodiaquine and artemether plus lumefantrine do not change the gut micro

197 sistant parasites, we compared AQ-13 against artemether plus lumefantrine for treatment of uncomplica

198 cipants were randomly assigned to either the artemether plus lumefantrine group or AQ-13 group by per

199 In the artemether plus lumefantrine group, two participants had

200 of the per-protocol analysis, the AQ-13 and artemether plus lumefantrine groups had similar proporti

201 on of patients who were cured was higher for artemether plus lumefantrine than for AQ-13 and the uppe

202 alysis suggested non-inferiority of AQ-13 to artemether plus lumefantrine.

203 a positive control the popular trioxane drug artemether plus mefloquine hydrochloride (average surviv

204 e conditions using the popular trioxane drug artemether plus mefloquine hydrochloride.

205 CM markedly increased survival compared with artemether plus vehicle only.

206 results offer a possible explanation for why artemether provides less advantage than might have been

207 f the breakdown of blood brain barrier after artemether treatment and decreased spleen congestion wit

208 iopoietin-2 (Ang-2) remained high 24 h after artemether treatment but returned to normal levels 24 h

209 creased risk of MFQ, MFQ-artesunate, and LUM-artemether treatment failures and pfmdr1 gene amplificat

210 Artemether treatment markedly aggravated anemia within 2

211 the standard trioxane drugs artemisinin and artemether were not parasiticidal.

212 GABA and the antimalarial drug artemether, which acts on GABAergic pathways, can drive